相关实验视频

Updated: Sep 10, 2025

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

针对罕见的BRAF突变黑色素瘤的向治疗:更新的多中心分析和公开的在线结果数据库的启动

Christian Menzer¹, Susanne Dugas-Breit¹, Martin Dugas²

¹Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ and University Hospital Heidelberg, Heidelberg, Germany.

European journal of cancer (Oxford, England : 1990)

|August 24, 2025

概括

在具有罕见BRAF突变的晚期黑色素瘤中,BRAF/ MEK抑制剂治疗显示出有效性. 组合疗法提供了最好的结果, 现在可获得罕见BRAF突变的全球数据库.

科学领域:

癌症学
遗传学
皮肤病学

背景情况:

对于V600E/K突变黑色素瘤,使用BRAF/MEK抑制剂是标准治疗.
在罕见BRAF突变的晚期黑色素瘤中,疗效尚不确定.
本研究分析了49名罕见BRAF突变的新患者的国际数据收集.

研究的目的:

评估BRAF/ MEK抑制剂治疗罕见BRAF突变的晚期黑色素瘤的疗效.
为了比较BRAF V600 (V600非E/K) 和非V600突变之间的结果.
开发一个公开可访问的全球罕见BRAF突变数据库.

主要方法:

在20个国际癌症中心对143名患者进行了回顾性分析.
对BRAF/ MEK抑制剂联合治疗 (BRAFi/ MEKi) 和单一治疗的评估.
收集临床结果,包括整体反应率 (ORR),无进展生存期 (PFS) 和整体生存期 (OS).

主要成果:

总体应答率 (ORR) 为35%,高于V600非E/ K (45%) 和非V600黑色素瘤 (26%).
组合治疗 (BRAFi/ MEKi) 在两组中显示出最佳结果.
具有特定罕见突变的患者 (V600D/ R,V600_ K601D/ E/ N,K601E/ N,L597V/ S/ R/ Q/ P/ K) 的PFS时间最长 (> 50个月).

结论:

在晚期黑色素瘤中,BRAF/ MEK抑制剂治疗对罕见的BRAF突变有益.
建议进行组合治疗以获得最佳结果.
已经建立了一个关于罕见BRAF突变的数据库.

关键词:

BRAFi 公司美国黑色素瘤不属于V600 罕见的 BRAF 突变针对性的治疗在V600

更多相关视频

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...